LONDON, UK: Hikma Pharmaceuticals Plc (HIK) has appointed Sigurdur (Siggi) Olafsson as chief executive officer (CEO). Said Darwazah, Hikma’s current chairman and CEO, will assume the position of executive chairman. These changes are effective immediately.
Olafsson was most recently president and CEO of global generic medicines group of Teva Pharmaceuticals, a position he held from 2014 to 2016.
Olafsson will also join Hikma’s board of directors as an executive director, subject to election at the next annual general meeting in May 2018.
With over 25 years of diverse pharmaceutical experience, Olafsson brings substantial commercial and operational capabilities and has a strong track record of driving performance and delivering growth. He has held many leadership roles at some of the world’s largest generic pharmaceutical companies, the company said.
As CEO, Olafsson will be responsible for the effective development and execution of Hikma’s corporate strategy, focusing on opportunities to accelerate the growth of the global business. All members of Hikma’s executive committee will report to Olafsson, who will report to Darwazah. He will initially be based in the US before relocating to Hikma’s head office in London, UK.
Read More: Hikma appoints former Teva executive as CEO
No comments:
Post a Comment